Clovis Highlights Pipeline Turnaround Going Into 2014
This article was originally published in Pharmaceutical Approvals Monthly
The small oncology company has recovered from previous setbacks and is now anticipating a strong year to come as it moves two drugs into later-stage development and pivotal trials.
You may also be interested in...
The failure of Clavis Pharma's and Clovis Oncology's novel potential pancreatic cancer therapy CP-4126/CO-101 in the pivotal LEAP trial was associated with the surprising failure of a novel personalized medicine approach to treating the devastating disease.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.